Google LLC has filed a new inter partes review petition at the Patent Trial and Appeal Board, opening IPR2026-00421 on July 13, 2026.

The Supreme Court has handed down a major administrative-law ruling, siding with President Donald Trump in a dispute over the firing of FTC Commissioner Rebecca Slaughter and sharply expanding presidential removal authority over independent agencies. In doing so, the Court overruled Humphrey’s Executor v. United States, the 1935 precedent that had long been understood to shield FTC commissioners from removal except for cause.

The case, Donald J. Trump, President of the United States, et al., Petitioners v. Rebecca Kelly Slaughter, is likely to become a cornerstone decision in the Court’s modern separation-of-powers jurisprudence.

A new inter partes review, IPR2026-00416, was filed on July 9, 2026 at the Patent Trial and Appeal Board, naming McCormick Company, Inc. in the proceeding. For patent practitioners tracking food technology, consumer products, and brand-adjacent innovation disputes, this is the kind of PTAB filing worth watching from the outset.

At this early stage, the docket information publicly available from the case caption primarily identifies the proceeding by the patent owner name, McCormick Company, Inc.. As is typical in a newly filed IPR, the key issues will center on which McCormick patent is being challenged, who the petitioner is, and whether the petition presents prior art grounds strong enough to justify institution. Those details often shape not only the PTAB strategy, but also any parallel district court or licensing dynamics.

In general, an IPR petition asks the Board to review the validity of one or more patent claims based on prior art patents or printed publications, usually under 35 U.S.C. §§ 102 or 103. Once the petition and supporting papers are fully available, practitioners will want to examine the asserted references, claim constructions, any expert declaration support, and whether the petitioner is pressing a narrow claim-focused attack or attempting a broader invalidation campaign.

This case may be especially relevant for in-house IP counsel and outside litigators because PTAB challenges involving established commercial players like McCormick can reveal a great deal about how competitors or accused infringers are approaching ingredient, formulation, packaging, processing, or related patent portfolios. Even before institution, the filing can signal market pressure points, identify art that may be reused against related family members, and preview arguments that could spill into co-pending litigation or post-grant strategy.

Patent owners will also want to watch for familiar procedural themes: discretionary denial issues, real-party-in-interest disputes, the sufficiency of motivation-to-combine arguments, and whether the petition relies on teachings that map cleanly onto the challenged claims.

The U.S. Supreme Court has handed down a major administrative-law ruling with immediate consequences for federal agencies, regulated businesses, and the lawyers who advise them.

A new post-grant review at the Patent Trial and Appeal Board is worth watching for practitioners tracking early-life patent challenges and the evolving use of PTAB proceedings against recently issued patents. In PGR2026-00064, titled ShoreShade LLC, the petition was filed on July 1, 2026. The proceeding is now on the radar for patent owners, petitioners, and IP counsel evaluating how aggressively to use post-grant review in high-stakes disputes.

At this stage, the docket caption identifies ShoreShade LLC as the patent owner in the PTAB proceeding.

A federal judge in Washington has preliminarily blocked the Defense Department from forcing New York Times reporters to be accompanied by escorts while they pursue their challenge to Pentagon press-access restrictions, a ruling that signals meaningful judicial skepticism toward the policy under the First Amendment.

The dispute, now pending as NEW YORK TIMES COMPANY et al v. DEPARTMENT OF DEFENSE et al, centers on whether the Pentagon can impose differential access burdens on a major news organization in a way that appears to impede routine newsgathering.

A new post-grant review, PGR2026-00062, was filed at the Patent Trial and Appeal Board on June 25, 2026, putting an America Ugreen Limited patent directly in the PTAB spotlight.

A new inter partes review filed at the Patent Trial and Appeal Board could be one to watch for companies operating at the intersection of life sciences, nutraceuticals, and consumer health. In IPR2026-00400, the proceeding is captioned Thorne Research, Inc. and was filed on June 22, 2026.

At this early stage, the PTAB docket signals that a patent challenge involving Thorne Research is underway, but practitioners should note that key details—including the specific patent claims at issue, the identity of the petitioner and patent owner as reflected in the styled papers, and the precise invalidity combinations asserted—may develop as the record fills out.

A new post-grant review, PGR2026-00062, was filed at the Patent Trial and Appeal Board on June 25, 2026, in a matter captioned America Ugreen Limited. While the publicly available docket caption immediately identifies Ugreen as a party, patent professionals will want to watch for the petition, mandatory notices, and patent owner filings to clarify the full party alignment, the challenged claims, and the commercial context behind the dispute.

At this stage, the key takeaway is procedural as much as substantive: a post-grant review is only available for patents subject to the AIA’s first-inventor-to-file regime and allows challengers to press a broader range of invalidity theories than inter partes review.

The Supreme Court’s June 23, 2026 disposition in No. 24-856 is notably concise: the judgment below was reversed and the case remanded. At least from the docket entry provided, the Court has not supplied an accompanying merits opinion in the materials summarized here. Even so, that procedural posture carries real significance for lawyers tracking the case and for practitioners thinking about next steps in the lower courts.

A reversal and remand means the Supreme Court concluded the lower court’s judgment cannot stand and that further proceedings are required.

Another PTAB proceeding has been filed against ResMed, with IPR2026-00341 entering the Patent Trial and Appeal Board on June 12, 2026. The petition places one of ResMed’s patents under inter partes review, opening a new front in what could become an important dispute for companies operating in the sleep-disorder and respiratory-device space.

At this stage, the publicly available docket identifies the proceeding by the title Resmed Corp., but practitioners will want to monitor the case record closely as the petition, mandatory notices, and related filings further clarify the specific patent claims at issue, the identity of all real parties in interest, and any parallel district court or ITC litigation that may shape the Board’s discretionary-review analysis.

As with any newly filed IPR, the key issues will center on which patent is being challenged, which claims are targeted, and what prior-art grounds are asserted. Typically, petitioners rely on anticipation and obviousness grounds under 35 U.S.C. §§ 102 and 103, supported by combinations of patents, printed publications, and expert declarations.

A new inter partes review, IPR2026-00387, was filed at the Patent Trial and Appeal Board on June 5, 2026, under the caption Optiver US LLC. At this early stage, the proceeding is notable less for a developed merits record and more for what it signals: another PTAB dispute involving a sophisticated market participant, with the potential to touch on commercially important technology and high-stakes parallel enforcement or licensing issues.

Based on the docket currently available, the proceeding names Optiver US LLC as the petitioner.

Another new inter partes review to watch at the Patent Trial and Appeal Board: IPR2026-00387, filed June 5, 2026, and captioned Optiver US LLC. At this early stage, the docket signals the start of a potentially important dispute for companies operating in technology-driven and latency-sensitive markets, but the petition itself will be the key document for practitioners looking to assess the full stakes of the case.

Based on the current docket entry, Optiver US LLC is the petitioner seeking review of an issued U.S. patent.

The Department of Justice has announced that a federal grand jury in the Eastern District of North Carolina has indicted former FBI Director James Comey on charges alleging threats to harm President Donald Trump. Whatever the ultimate merits, the case is immediately significant because it combines a high-profile defendant, allegations involving threats against a sitting or former president, and the likelihood of fast-moving appellate and procedural litigation.

For legal professionals, this is the kind of prosecution that will be watched as closely for its procedural posture as for its political implications.

Samsung Electronics Co., Ltd. has filed a new inter partes review petition at the Patent Trial and Appeal Board, opening IPR2026-00337 on April 15, 2026. The proceeding places another potentially significant patent dispute on the PTAB’s docket and gives patent practitioners an early look at what may become an important validity fight involving Samsung as petitioner.

At this stage, the publicly available case caption identifies Samsung Electronics Co., Ltd. as the petitioner, but practitioners should watch the docket closely for the patent owner’s formal identification, the challenged patent number, and the specific claims at issue as those details become more fully reflected in the record.